maxwell pardon - Imagemakers
ISP-001 was developed using Immusofts proprietary platform ISP (Immune System Programming). To manufacture the cell product, Immusoft also uses technology related to the.
ISP-001 was developed using Immusofts proprietary platform ISP (Immune System Programming). To manufacture the cell product, Immusoft also uses technology related to the.
Our approach, called Immune System Programming (ISP) entails collecting a type of the patients immune cells, called B cells. In response to immune stimulation, B cells can turn into biofactories.
Immusoft acquired the system when it bought Discovery Genomics in 2016 for an undisclosed price, gaining a license to use Sleeping Beauty for MPS I plus options to license the...
Understanding the Context
Safety and initial activity of autologous human B cells genetically engineered to express human iduronidase using the Sleeping Beauty transposon system. Results from a first-in-human...
Safety and initial activity of autologous human B cells genetically engineered to express human iduronidase using the Sleeping Beauty transposon system. Results from a first-in-human.
This hybrid cell/gene therapy approach uses a clinically validated, non-viral vector for safe, reliable insertion of functional genes into immune cells using the Sleeping Beauty (SB) transposon system.
The company has developed a technology platform called Immune System Programming (ISP), which modifies a patient's B cells and instructs the cells to produce gene-encoded medicines.
Key Insights
Immusoft acquired the system when it bought Discovery Genomics in 2016 for an undisclosed price, gaining a license to use Sleeping Beauty for MPS I plus options to license the.
This is a Phase 1, first-in-human, open-label, single-arm study in which patients with Mucopolysaccharidosis Type I Hurler-Scheie and Scheie are treated with autologous plasmablasts.
Safety and Efficacy of Encapsulated Allogeneic MPS-1 Therapy ISP-001: Sleeping Beauty Transposon-Engineered B Cells for MPS I Evaluation of Intravenous Laronidase Pharmacokinetics Before and.
